AntalGenics as Externalized R&D Organization (ERDO) develops customized R&D projects completely personalized and designed based on your specific requirements.
AntalGenics develops the technology which is necessary to accomplish your goals. AntalGenics actively participates in the project design, intellectual property generation and commercialization of your final products.
Modeling ligand-receptor type
Sequence space scanning
Genomic screening Improved affinity and stability
Second site suppressor designs (compensatory mutagenesis)
Targeted molecular design
Building of peptide ligands in the binding site
Design of peptide inhibitors of interactions
Location of the interaction sites of a given protein structure
Protein-protein docking (-lípids, -nucleotides, -carbohydrates, etc)
Protein-drug (nucleotide-drug) docking
Molecular dynamics from crystallographic structures
Steered Molecular Dynamics
Simulation of real conditions: membranes, ion, solvent, pH, etc.
Simulation of protonation / deprotonation states
Prediction of stability energy
Increased thermal stability
Modeling of mini-proteins
Based on structure (necessary 3D)
Based on the flexibility of the ligand
Based on pharmacophore (3D necessary)
Based on molecular assemblies
Ligand-based (3D not necessary)
Ligand-based pharmacophore search
Structure similarity ligand search
Protein-drug from a database of any size
Modeling of soluble proteins (by homology)
Modeling of membrane protein (by homology)
Modeling of peptides
Check structures and problem solving
Matching of structures and density maps obtained by cryo-electron microscopy
Derived from databases
Markush enumeration (base molecule with variable positions)
Peptide library (peptides with a length of 3 to 7 aa) N- and C- free or protected
In AntalGenics we are using state-of-the-art technologies to test thousands of compounds and our extensive experience in the development and automation of techniques for the implementation in projects of high throughput screening. For this purpose, there are different units dedicated to the evaluation of the pharmacological activity of molecules that includes the facilities to carry out large-scale screening.
The platform is able to carry out functional tests of different ion channels, enzyme assays (phosphodiesterases, kinases, phosphatases), cytotoxicity assay in different cell lines (including human tumor lines), solubility tests and preliminary pharmacokinetic and Toxicology tests.
Our professional staff is specialized in the evaluation of different aspects of the screening planning, validation of targets, drug discovery, design and automation of tests, and in the use of software needed for the storage and automated data analysis. In addition, this platform is complemented by the in silico screening unit.